Apogee Therapeutics, Inc. Common Stock (APGE) Stock Price
APGEStock
$135.07+253.96%52W
Market Cap$10.22B
P/E—
PEG Ratio—
Div yield—
Beta-1.04
APGE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)81.42%
Price vs S&P 500 (4W)0.87%
VGM Score94.27
APGE Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.96 | -$1.08 | -12.39%(-$0.12) | |
| Q1 2026 | -$1.13 | -$1.06 | +6.30%(+$0.07) | |
| Q4 2025 | -$1.04 | -$1.03 | +0.73%(+$0.01) | |
| Q3 2025 | -$1.15 | -$1.11 | +3.35%(+$0.04) | |
| Q2 2025 | -$1.05 | -$1.13 | -7.93%(-$0.08) |
APGE Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.20
3.48
3.48
3.38
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
APGEApogee Therapeutics, Inc. Common Stock | — | — | A | — | — | — | — | $135.07 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics develops engineered monoclonal antibodies targeting atopic dermatitis, COPD, and other inflammatory and immunology indications with significant unmet medical need. The company's differentiated programs leverage optimized antibody engineering to overcome limitations of existing therapies by targeting validated mechanisms of action.